Liège-based Surgical Imaging Startup SamanTree Medical Secures €20M From EIB

The funding is supported by InvestEU the EU’s flagship programme mobilising over €372 billion in investment from 2021–2027.

In the 2025 European MedTech and HealthTech funding landscape, SamanTree Medical’s €20 million financing ranks among the larger rounds supporting clinically focused imaging and diagnostic innovation.

Other notable rounds include PIUR IMAGING (€5.6M for tomographic 3D ultrasound) and Juisci (€5.5M for an AI platform aiding healthcare professionals) while M2care raised €26M to expand its HealthTech venture studio.

Read Also - Stockholm-Based Brickanta Raises $8M Seed Funding For Construction AI Platform

Collectively, these deals total around €37 million in imaging-related and adjacent HealthTech investments in 2025 (excluding SamanTree).

Its larger ticket size and focus on intraoperative, real-time imaging hardware underscore sustained institutional backing for capital-intensive medical device innovation contrasting with smaller software-focused rounds elsewhere in the sector.

“The support of the European Investment Bank represents an important milestone for SamanTree,” says Olivier Delporte CEO of SamanTree Medical. “This financing allows us to accelerate development of the Histolog Scanner and expand our commercial presence across Europe and the United States. The rigorous due diligence process undertaken by the EIB reflects the importance of our innovative technology, our development plan and our long-term vision for advancing real-time, high-resolution imaging for excised tissue.”

Founded in 2014, SamanTree Medical is on a mission to improve oncologic surgery through innovative imaging solutions. Its Histolog Scanner captures nearly 30,000 images simultaneously, producing high-resolution, histology-like images in about one minute without damaging tissue.

This enables surgeons and pathologists to assess tissue intraoperatively, identifying residual abnormal cellular microstructures while the patient remains on the operating table. To date the device has been used in over 6,000 patients demonstrating significant impact across multiple tissue types.

In breast-conserving surgery, the SHIELD study reported that using Histolog images reduced reoperation rates from 30% to 10%, a 67% reduction. For prostatectomies, Histolog provides results comparable to intraoperative frozen-section analysis the gold standard while reducing imaging and interpretation time from 45–60 minutes to 5–20 minutes.

Clinical studies show the scanner delivers sensitivity between 73–91% and specificity between 91–100% compared to conventional pathology. Intraoperative assessment with Histolog has also enabled more nerve-sparing prostate surgeries significantly lowering the risk of erectile dysfunction.

The new financing will support SamanTree Medical’s R&D and innovation activities including continued development of the Histolog Scanner and its applications in oncologic surgery.

“Our investment in SamanTree Medical reflects the EIB’s long-standing commitment to advancing medical innovation across Europe ” said EIB Director Alessandro Izzo. “By supporting med‑tech companies through venture debt, a tool that helps entrepreneurs accelerate growth and bring cutting-edge technologies to patients sooner, we make sure that key medical tech companies can grow and thrive in Europe.

“Supporting innovators like SamanTree Medical is central to our mission of driving positive impact for patients and healthcare systems.”